References of "ONESTI, Concetta Elisa"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Onesti, Concetta Elisa ULiege; Jerusalem, Guy ULiege

in Expert review of anticancer therapy (2021), 21(3), 283-298

Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved.Areas covered: Here, we analyze the ... [more ▼]

Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved.Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbociclib and ribociclib showed high rates of hematological toxicity, primarily neutropenia, and were associated with a low rate of severe infections. Abemaciclib was associated with a high rate of gastrointestinal toxicities, primarily diarrhea, of grade 1-2 in most cases. Ribociclib was associated with a high rate of hepatic, and respiratory toxicity and with QTc prolongation. The toxicity rate of ribociclib was higher in metastatic patients than non-metastatic patients, with approximately 33% more grade 3-4 toxicities and 21% more grade 3-4 neutropenic events. A 5% higher risk of diarrhea was observed in postmenopausal patients. Pre-treated patients did not show a higher toxicity rate for palbociclib/ribociclib than previously untreated patients, while a 26% higher risk of any grade neutropenia and 6% higher risk of grade 3-4 diarrhea were observed with abemaciclib.Expert opinion: Considering the similar efficacies and indications of palbociclib, ribociclib, and abemaciclib, the evaluation of their toxicity profiles may facilitate treatment choice. [less ▲]

Detailed reference viewed: 39 (4 ULiège)
Full Text
Peer Reviewed
See detailHigh plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer
Onesti, Concetta Elisa ULiege; JOSSE, Claire ULiege; Boulet, Delphine ULiege et al

in Tumori Journal (2020, October 31)

Background: The immune system has a role in breast tumor, in particular in triple negative (TNBC) and in hormone receptor-negative/HER2-positive breast cancers. The aim of this study is to analyze the ... [more ▼]

Background: The immune system has a role in breast tumor, in particular in triple negative (TNBC) and in hormone receptor-negative/HER2-positive breast cancers. The aim of this study is to analyze the association between baseline cytokines expression with cancer relapse and outcome. Material and methods: Baseline plasmatic samples of 66 stage I-III breast cancers treated with surgery with or without radiotherapy and systemic treatment between 2011 and 2017 were collected. A panel of 24 cytokines were analyzed by Luminex MAGPIX technology, using multiplex Luminex Magnetic Assay kits (®R&D System). Results: Sixty-six breast cancer patients were included in the study. The median follow-up was of 78 months (range 18-99). The median age at diagnosis was of 58.5 years (range 32-86). The stage at diagnosis was I in 29 (43.9%) patients, II in 26 (39.4%) and III in 11 (16.7%). The histological type was ductal in 47 cases (71.2%), lobular in 13 (19.7%) and mixed in 6 (9.1%). Fifty-three (80.3%) patients were estrogen-receptor-positive, 11 (16.7%) HER2-positive and 12 (18.2%) TNBC. All the patients received surgery, combined with neo/adjuvant chemotherapy in 35 (53%) cases, anti-HER2 in 9 (13.6%), hormonotherapy in 53 (80.3%) and radiotherapy in 52 (78.8%). During the follow-up we observed 11 relapses and 4 deaths. IL-4 was associated with relapse, that occurs in 30.7% of the cases in the group with IL-4 > 0.07 (IL4-H) mean fluorescence intensity (MFI) vs in 7.5% in the group with IL-4 ⩽ 0.07 MFI (IL4-L) (p 0.013), with a ROC curve AUC of 0.745. In multivariate analysis relapse was associated with IL-13 (p 0.048) and T stage (p 0.049). Survival analysis showed a better time to treatment failure (TTF) for the group IL4-L (5y-TTF 87% vs 63% for IL4-L and IL4-H, p 0.022) and for the group with IL-13 ⩽ 0.1 MFI (IL13-L) compared IL-13 > 0.1 MFI (IL13-H) (5y-TTF 90% vs 45%, p 0.017). A separation of the curves was also observed for breast cancer specific survival (5y-BCSS: 95% vs 84% for IL4-L vs IL4-H, p 0.118; 91% vs 75% for IL13-L vs IL13-H, p 0.029). Conclusions: Higher baseline plasmatic level of IL-4 and IL-13 are associated with a worse prognosis in early stage breast cancer. These are two structurally and functionally related cytokines known for regulating the immune system activity, leading to a T helper-2 response and to a macrophage M2 polarization. Data should be confirmed in a larger cohort and a mechanistic study is advisable. [less ▲]

Detailed reference viewed: 34 (7 ULiège)
Full Text
Peer Reviewed
See detailThe relative eosinophil count in breast cancer as an emerging prognostic biomarker
ONESTI, Concetta Elisa ULiege; JOSSE, Claire ULiege; Beaumecker, Barbara ULiege et al

in European Journal of Cancer (2020, October 02)

Background: Cancer outcome appears to be affected by circulating immune cells in several tumor types. The role of peripheral eosinophils was widely studied in melanoma, while less data are available for ... [more ▼]

Background: Cancer outcome appears to be affected by circulating immune cells in several tumor types. The role of peripheral eosinophils was widely studied in melanoma, while less data are available for breast cancer (BC) so far. In a previous study, we showed an association between baseline relative eosinophil count (REC), pathological complete response and survival rate in triple negative and hormone receptor negative/HER2 positive breast cancer. In this retrospective study we analyzed the role of REC in all breast cancer subtypes at time of diagnosis and during follow-up. Material and Methods: Stage I-III BC patients (pts) treated between 1999 and 2018 were included in the study. REC and relative lymphocyte count (RLC) at seven different timepoints were collected. The pts were divided into two groups according to REC, using 1.5% as threshold, and according to RLC, using 17.5% as threshold. The co-primary endpoints were the BC specific survival (BCSS) and the time to treatment failure (TTF) according to REC. The secondary endpoints were: BCSS and TTF according to RLC, the association between REC and RLC with relapse; the variation of REC during follow-up and at relapse. Statistical analysis was done with SPSS v25 software. Results: Overall 930 early BC pts were included in the study. The median age of the whole cohort was 61 years (25–97). The pts were well balanced according to the TNM stage in the group REC-low (393 pts) and in the group REC-high (597 pts): 30.5% and 32.9% stage I; 45.3% and 45.1% stage II; 22.6% and 21.4% stage III respectively; 1.4% unknown. After a median follow-up of 91 months (range 1–245) we observed a benefit in TTF (HR 0.610–95% CI 0.458–0.812, p 0.001) and BCSS (HR 0.632–95%CI 0.433– 0.923, p 0.018) in REC-high vs REC-low group. A survival benefit was observed also in the RLC-high vs RLC-low group (TTF: HR 0.421–95% CI 0.262–0.677, p 0.001; BCSS: HR 0.350–95% CI 0.2–0.614, p 0.001). A lower rate of relapse was observed in the REC-high vs REC-low group (17.1% vs 24.7%, p 0.005) and in the RLC-high vs RLC-low group (19.4% vs 35.8%, p 0.004). We observed a lower median REC at baseline before surgery (1.8% and 1.4% in pts without and with relapse respectively), compared to the median value after surgery (2.7% and 2.5% respectively), that remain stable until 10 years of postsurgical follow up in cancer free pts. A decrease in median REC was detected at time of relapse (1.5%). All the differences observed in the groups of pts with and without tumor recurrence were statistically significant (p < 0.0001), suggesting a role of the presence of cancer in the modulation of eosinophil count. Conclusions: REC could be a new promising, affordable and accessible predictive and prognostic biomarker in all BC subtypes. Mechanistic studies, ongoing in our laboratory, are needed to understand eosinophils’ physiopathological role. [less ▲]

Detailed reference viewed: 33 (4 ULiège)
Full Text
Peer Reviewed
See detailExpected medium and long term impact of the COVID-19 outbreak in oncology
JERUSALEM, Guy ULiege; ONESTI, Concetta Elisa ULiege; Generali, Daniele et al

in Annals of Oncology (2020, September 19)

Background: The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide. Methods: A 95 items survey was distributed worldwide by 20 ... [more ▼]

Background: The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease (COVID-19) is challenging cancer care and services worldwide. Methods: A 95 items survey was distributed worldwide by 20 oncologists from 10 of the most affected countries in order to evaluate the impact on organization of oncological care. Results: 109 representatives from oncology centers in 18 countries (62.4% academic hospitals) filled out the survey (June 17 e July 14, 2020). A swab or gargle test is systematically performed before day care unit or overnight stay admissions in 27.5% and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing (77.1%) of infected patients was organized in many centers. Treatment modalities mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in 32.1% of centers, and 64.2 % of participants agree that under-treatment is a major concern. At the pandemic peak, teleconsultations were performed for follow-up (94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy (57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that they will continue to use telemedicine. Most participants reported more frequent use of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree that virtual meetings are an acceptable alternative to live international meetings. Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4% had an increased scientific activity. Only 18% of participants estimate that their wellbeing will not recover to previous levels by the end of the year; 63% indicate easily accessible psychological support for caregivers, but only 10% used or planned to use it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers. Major study protocol violations/deviations were observed in 27.5% and significant reductions of clinical trial activities are expected by 37% of centers this year. Conclusions: COVID-19 has a major impact on organization of patient care, well-being of caregivers, continued medical education and clinical trial activities in oncology. [less ▲]

Detailed reference viewed: 64 (9 ULiège)
Full Text
Peer Reviewed
See detailDisparities in access to oncology clinical trials in Europe in the period 2009-2019
Carneiro, Ana; Amaral, Teresa; Brandao, Mariana et al

in Annals of Oncology (2020, September 19)

Background: Clinical trials are essential for advancing cancer treatment. Yet, there is limited data on their distribution and access in Europe. To ascertain the extent of potential inequalities in access ... [more ▼]

Background: Clinical trials are essential for advancing cancer treatment. Yet, there is limited data on their distribution and access in Europe. To ascertain the extent of potential inequalities in access to clinical trials in Europe, we compared their distribution among European countries. Methods: The Clinicaltrials.gov database was searched for interventional clinical trials in adults with neoplasms. Available data from phase I-III trials between 06/2009 to 06/2019 in Europe were retrieved. We considered the number of clinical trials registered in each country and one “trial-entry” was defined as one trial/country. Results: In total, 18454 trial-entries were identified, of which 12% were phase I, 10% phase I/II, 32% phase II, 2% phase II/III and 44% phase III; 74% were industry-sponsored, 15% were academic and 11% were an academic/industry partnership. The number of trials per country varied from 2.48 in Central/Eastern Europe to 5.33/100 000 inhabitants in Northern Europe. The proportion of phase I-II trials was higher in the Southern and Western regions (13-15%) compared to Central/Eastern and Northern regions (4-9%). The number of trial-entries/100 000 inhabitants/country ranged from 0.14 (Albania) to 10.7 (Belgium). Between 2010 and 2018, the total number of trials per country in Europe increased by 33%. The increase in early-phase trials was larger (phase I-II, 61%) than in late-phase trials (phase II-III, 7%). Portugal, Ireland, Finland, Greece and Norway registered the largest percentage increase in early-phase trials, while Ireland, Spain, Norway, Italy and Belgium led the largest percentage increase in late-phase trials. Five countries dominated in terms of an increase in the absolute number of total trial-entries in both early- and late-phase trials: Spain (90/40), France (45/16), UK (45/13), Italy (38/19) and Belgium (35/12). During this period there was no significant variation in the distribution of industry and academic sponsored trials but an increase in industry/academic partnerships was observed (= 8%). Conclusions: The number of clinical trials varies greatly among European regions resulting in potential asymmetries in patients’ access to clinical trials. The disparities in access to oncology trials need to be addressed by all the stakeholders. [less ▲]

Detailed reference viewed: 36 (4 ULiège)
Full Text
Peer Reviewed
See detailOncological care organisation during COVID-19 outbreak
ONESTI, Concetta Elisa ULiege; Rugo, Hope S; Generali, Daniele et al

in ESMO Open (2020), 5

Detailed reference viewed: 35 (6 ULiège)
Full Text
Peer Reviewed
See detailBlood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse
ONESTI, Concetta Elisa ULiege; JOSSE, Claire ULiege; Boulet, Delphine ULiege et al

in Oncoimmunology (2020)

Background: Cancer outcome is associated with circulating immune cells, including eosinophils. Here we analyze the relative eosinophil count (REC) in different breast cancer subtypes. Methods: Stage I–III ... [more ▼]

Background: Cancer outcome is associated with circulating immune cells, including eosinophils. Here we analyze the relative eosinophil count (REC) in different breast cancer subtypes. Methods: Stage I–III breast cancer patients were included in the study and classified as REC-high vs low (cutoff 1.5%) or relative lymphocyte count (RLC)-high vs low (cutoff 17.5%). The co-primary endpoints were the breast cancer-specific survival (BCSS) or the time to treatment failure (TTF) in the REC groups. Results: Overall 930 patients were included in the study. We observed a benefit for REC-high vs REC-low in TTF (HR 0.610, 95% CI 0.458–0.812), and in BCSS (HR 0.632, 95% CI 0.433–0.923). Similarly, we observed a better TTF (HR 0.421, 95% CI 0.262–0.677) and BCSS (HR 0.350, 95% CI 0.200–0.614) in RLC-high vs low. A lower relapse rate was observed in the REC-high vs REC-low group (17.1% vs 24.7%, p = 0.005), not confirmed in the multivariate analysis. A lower median REC at baseline and at relapse was observed compared to REC after surgery and during cancer-free follow-up (p < .0001). Conclusions: REC could be a new promising, affordable and accessible predictive and prognostic biomarker in all breast cancer subtypes. [less ▲]

Detailed reference viewed: 43 (14 ULiège)
Full Text
Peer Reviewed
See detailFour lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis
Onesti, Concetta Elisa ULiege; Iacono, D.; Angelini, S. et al

in Anti-Cancer Drugs (2019), 30(2), 201-204

Lung cancer is the most common tumor and the leading cause of cancer-related death worldwide. Approximately 6.7% of non-small-cell lung cancers (NSCLCs) show anaplastic lymphoma kinase (ALK) rearrangement ... [more ▼]

Lung cancer is the most common tumor and the leading cause of cancer-related death worldwide. Approximately 6.7% of non-small-cell lung cancers (NSCLCs) show anaplastic lymphoma kinase (ALK) rearrangement and could benefit from ALK-targeted treatment. Various anti-ALK drugs have been developed during the past years, but it is actually controversial which sequence and which ALK inhibitor is recommended for a single patient. Leptomeningeal carcinomatosis (LC) is associated with a poor prognosis, with an overall survival of 2-4 months for treated patients. The data about LC management derive mainly from retrospective studies, being an exclusion criterion for most trials. Intrathecal chemotherapy and whole-brain radiotherapy (WBRT), associated with a systemic treatment, are the most commonly used approach. Here we present a case of NSCLC harboring an ALK translocation treated with four lines of ALK inhibitors and receiving WBRT for LC, showing an overall survival of ∼5 years from the diagnosis of metastatic disease. This case report focuses mainly on several controversial clinical aspects, that is, the sequence of treatment in ALK-positive NSCLC, the ALK inhibitors' efficacy on brain disease and beyond progression, the management of LC, and the role of WBRT despite the risk of cognitive impairment. [less ▲]

Detailed reference viewed: 35 (2 ULiège)
Full Text
Peer Reviewed
See detailTryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
ONESTI, Concetta Elisa ULiege; BOEMER, François ULiege; JOSSE, Claire ULiege et al

in Journal of Translational Medicine (2019), 17

Background: Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosuppressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is ... [more ▼]

Background: Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosuppressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is expressed in many cancer types, including breast cancer. Here, we analyze kynurenine and tryptophan and their ratio in breast cancer patients and healthy controls. Methods: Breast cancer patients and healthy controls were prospectively enrolled in our study. All subjects underwent blood sample withdrawal at diagnosis or on the day of screening mammography for the healthy controls. Plasmatic kynurenine and tryptophan were determined on a TQ5500 tandem mass spectrometer after chromatographic separation. Results: We enrolled 146 healthy controls and 202 women with stages I–III breast cancer of all subtypes. All patients underwent surgery, 126 underwent neoadjuvant chemotherapy with 43 showing a pathological complete response, and 43 underwent adjuvant chemotherapy. We observed significantly higher plasmatic kynurenine, tryptophan and their ratio for the healthy controls compared to patients with breast cancer. We observed a lower plasmatic tryptophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone receptor-positive cancers. Lobular cancers showed a lower ratio than any other histologies. Advanced cancers were associated with a lower tryptophan level and higher grades with an increased kynurenine/tryptophan ratio. Pathological complete response was associated with higher kynurenine values. The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratios were not predictive of survival. Conclusions: The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratio could differentiate breast cancer patients from healthy controls. The Kyn/Trp ratio and Trp also showed different values according to hormone receptor status, TNM stage, T grade and histology. These results suggest a rapid metabolism in breast cancer, but no associations with outcome or sensitivity to chemotherapy were observed. [less ▲]

Detailed reference viewed: 43 (8 ULiège)
Full Text
Peer Reviewed
See detailPredictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
ONESTI, Concetta Elisa ULiege; JOSSE, Claire ULiege; Poncin, Aurélie ULiege et al

in Oncotarget (2018)

In current clinical practices, up to 27% of all breast cancer patients receive neoadjuvant chemotherapy. High pathological complete response rate is frequently associated with tumor-infiltrating ... [more ▼]

In current clinical practices, up to 27% of all breast cancer patients receive neoadjuvant chemotherapy. High pathological complete response rate is frequently associated with tumor-infiltrating lymphocytes. Additionally, circulating immune cells are also often linked to chemotherapy response. We performed a retrospective analysis on a cohort of 112 breast cancer patients (79 triple-negative, 33 hormone receptor-negative/HER2-positive) treated with standard neoadjuvant chemotherapy. Eosinophil and lymphocyte counts were collected from whole blood at baseline and during follow-ups and their associations with pathological complete response, relapse, disease-free and breast cancer-specific survival were analyzed. We observed a higher pathological complete response rate in patients who presented at baseline a relative eosinophil count ≥ 1.5% (55.6%) than in those with a relative eosinophil count < 1.5% (36.2%)(p = 0.04). An improvement in breast cancerspecific survival in patients with high relative eosinophil count (p = 0.05; HR = 0.336; 95% CI = 0.107–1.058) or with high relative lymphocyte count (threshold = 17.5%, p = 0.01; HR = 0.217; 95% CI = 0.060–0.783) were also observed. Upon combining the two parameters into the eosinophil x lymphocyte product with a threshold at 35.8, associations with pathological complete response (p = 0.002), relapse (p = 0.028), disease-free survival (p = 0.012) and breast cancer-specific survival (p = 0.001) were also recorded. In conclusion, the relative eosinophil count and eosinophil x lymphocyte product could be promising, affordable and accessible new biomarkers that are predictive for neoadjuvant chemotherapy response and prognostic for longer survival in triplenegative and hormone receptors-negative/HER2-positive breast cancers. Confirmation of these results in a larger patient population is needed. [less ▲]

Detailed reference viewed: 70 (10 ULiège)
Full Text
See detailPredictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment.
ONESTI, Concetta Elisa ULiege; JOSSE, Claire ULiege; PONCIN, Aurélie ULiege et al

Scientific conference (2018, September 13)

Introduction: In clinical practices, up to 27% of breast cancer (BC) patients receive neoadjuvant chemotherapy (NAC). In this context, a pathological complete response (pCR) is the most commonly used end ... [more ▼]

Introduction: In clinical practices, up to 27% of breast cancer (BC) patients receive neoadjuvant chemotherapy (NAC). In this context, a pathological complete response (pCR) is the most commonly used end-point. High pCR rate is frequently associated with tumor infiltrating lymphocytes. Besides, circulating immune cells are also often linked to chemotherapy response. Materials and methods: We performed a retrospective analysis on 112 BC patients (79 triple negative, 33 HR-/HER2+), treated with standard NAC. The median follow-up was 37.5 months (range 9-156). Eosinophil and lymphocyte count were collected at baseline, after surgery, at 1 year of follow-up and at relapse. The primary end-point is the association between the relative eosinophil count (REC) and pCR. The secondary end-points are the associations of REC, relative lymphocyte count (RLC) and eosinophil/lymphocyte product (ELP) with relapse, disease free (DFS) and breast cancer specific (BCSS) survival and to study the variation of REC and RLC during follow-up. Results: We observed a higher pCR rate in patients with REC≥1.5% vs patients with REC <1.5% (55.6% vs 36.2%, p = 0.04), and a higher median REC in patients with pCR (1.9% vs 1.2%, p 0.042). No statistically significant associations were detected with relapse, nor between RLC with pCR or relapse. We observed a 3-year BCSS of 91% vs 80% for high and low REC respectively (p 0.05; HR 0.336, 95% CI 0.107-1.058) and of 88% vs 49% in RLC≥17.5% and <17.5% respectively (p 0.01; HR 0.217, 95% CI 0.060-0.783). No significant differences were detected for DFS. Combining the two parameters in the ELP, we observed an association with pCR (59.6% in ELP≥35.8 vs 30.9% in ELP<35.8, p 0.002), relapse (12.3% vs 29.1% in high and low ELP, p 0.028), DFS (3-year DFS 90% vs 69% in high and low ELP, p 0.012; HR 0.337, 95% CI 0.138-0.823) and BCSS (3-year BCSS 95% vs 75% in high and low ELP, p 0.001; HR 0.129, 95% CI 0.029-0.573). Moreover, we observed a raise of REC after surgery from 1.4% to 2.6% (p 0.0001) and a significant reduction at relapse from 2.8% to 1.7% (p 0.021). Conversely, a reduction of RLC from 26.9% at baseline to 20.45% after surgery (p 0.0001), without significant variation at relapse, was detected. Conclusion: REC, RLC and ELP could be new promising, affordable and accessible biomarkers predictive for NAC response and prognostic for longer survival in TNBC and HR-/HER2+ BC. Confirmation in a larger cohort is needed. [less ▲]

Detailed reference viewed: 49 (7 ULiège)
Full Text
Peer Reviewed
See detailPrognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival.
Roberto, Michela; Botticelli, Andrea; Strigari, Lidia et al

in Medical Oncology (2018), 35(7), 111

This study aimed to identify clinicopathological factors associated with the outcome of elderly patients with gastric cancer (GC), and to construct a nomogram for individual risk prediction. Tumor ... [more ▼]

This study aimed to identify clinicopathological factors associated with the outcome of elderly patients with gastric cancer (GC), and to construct a nomogram for individual risk prediction. Tumor characteristics of 143 patients aged ≥ 80 years underwent surgery for GC were collected and analyzed by uni- and multivariate analyses. A prognostic nomogram was constructed using the factors which resulted to be significantly associated with overall survival. Discrimination of nomogram was tested by Kaplan-Meier (KM) curves and boxplots. With a median follow up of 18.37 months, overall 1-year survival rate was 51% and it was 60 and 40% for older and younger than 83 years, respectively (P = 0.003). Univariate analysis indicated that age (P = 0.008), pre-operatory performance status (P < 0.001), depth of invasion (P = 0.007), lymph nodes involvement (P < 0.001), and residual tumor (P < 0.001) were significant prognostic factors. Based on these variables, a nomogram to predict 3, 6, 12, and 24 months survival probability after GC surgery was developed. KM and boxplots according to the range of nomogram total points highlighted the appropriateness of distinguish the patients' survival in all the subgroups. Moreover, this nomogram exhibited superior prognostic discrimination between intermediate stages (II-III) than AJCC-TNM classification. This study showed that after good surgical selection, the prognosis of elderly GC patients may be influenced by several clinicopathological factors. Therefore, a predictive nomogram to distinguish more accurately fit patients may allow physicians to individualize treatments and to detect those patients who may benefit from an intensive multidisciplinary approach. [less ▲]

Detailed reference viewed: 23 (2 ULiège)
Full Text
Peer Reviewed
See detailThe key role of kynurenine in antiPD-1 failure
Botticelli, Andrea; Cerbelli, Bruna; Lionetto, Luana et al

in Cancer Research (2018, April 14)

Detailed reference viewed: 21 (1 ULiège)
Full Text
Peer Reviewed
See detailMolecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice
Milano, Annalisa; Mazzetta, Francesca; Valente, Sabatino et al

in Analytical Cellular Pathology (2018)

Detailed reference viewed: 58 (1 ULiège)
Full Text
Peer Reviewed
See detailHyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report.
Occhipinti, Mario; Falcone, Rosa; ONESTI, Concetta Elisa ULiege et al

in Drug Safety - Case Reports (2018), 5(1), 12

Detailed reference viewed: 70 (6 ULiège)
Full Text
Peer Reviewed
See detailLean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
Mazzuca, Federica; ONESTI, Concetta Elisa ULiege; Roberto, Michela et al

in Oncotarget (2018)

Detailed reference viewed: 46 (4 ULiège)